Related Experiment Video
Updated: May 20, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET
Alessandro Gozzetti1, Vania Rossi, Alfonso Cerase
1Division of Hematology, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Summary
A 71-year-old woman with multiple myeloma experienced back pain, but imaging ruled out relapse. Single-agent lenalidomide treatment led to complete disappearance of lesions, confirmed by CT/PET scans.
Area of Science:
- Oncology
- Hematology
- Medical Imaging
Background:
- Multiple myeloma is a cancer of plasma cells.
- Autologous stem cell transplant (ASCT) is a common treatment for multiple myeloma.
- Relapse can occur years after ASCT, presenting diagnostic challenges.
Observation:
- A 71-year-old female with a history of multiple myeloma presented with back pain seven years post-ASCT.
- Initial skeletal bone survey and MRI did not reveal evidence of relapse.
- Computed tomography/positron emission tomography (CT/PET) scans were negative for disease recurrence.
Findings:
- Single-agent lenalidomide therapy was initiated for the patient.
- Complete disappearance of myeloma-related lesions was observed after six months of lenalidomide treatment.
- The treatment response was confirmed at one-year follow-up CT/PET scans.
Implications:
- Lenalidomide monotherapy can be effective in managing late-onset multiple myeloma lesions after ASCT.
- CT/PET imaging is crucial for accurate relapse assessment in multiple myeloma.
- This case highlights the potential for effective treatment even in the absence of clear radiological relapse evidence.
